Objective: The surgical eradication of malignant glioma cells is theoretically impossible. Therefore, reducing the number of remaining tumor cells around the brain–tumor interface (BTI) is crucial for achieving satisfactory clinical results. The usefulness of fluorescence–guided resection for the treatment of malignant glioma was recently reported, but the detection of infiltrating tumor cells in the BTI using a surgical microscope is not realistic. Therefore, we have developed an intraoperative rapid fluorescence cytology system, and exploratorily evaluated its clinical feasibility for the management of malignant glioma. Materials and methods: A total of 25 selected patients with malignant glioma (newly diagnosed: 17; recurrent: 8) underwent surgical resection under photodiagnosis using photosensitizer Talaporfin sodium and a semiconductor laser. Intraoperatively, a crush smear preparation was made from a tiny amount of tumor tissue, and the fluorescence emitted upon 620/660 nm excitation was evaluated rapidly using a compact fluorescence microscope in the operating theater. Results: Fluorescence intensities of tumor tissues measured using a surgical microscope correlated with the tumor cell densities of tissues evaluated by measuring the red fluorescence emitted from the cytoplasm of tumor cells using a fluorescence microscope. A “weak fluorescence” indicated a reduction in the tumor cell density, whereas “no fluorescence” did not indicate the complete eradication of the tumor cells, but indicated that few tumor cells were emitting fluorescence. Conclusion: The rapid intraoperative detection of fluorescence from glioma cells using a compact fluorescence microscope was probably useful to evaluate the presence of tumor cells in the resection cavity walls, and could provide surgical implications for the more complete resection of malignant gliomas.
One of the key factors contributing to the poor prognosis of glioblastoma is the treatment resistance of glioma stem cells (GSCs). In this study, the authors used MGG8, a patient-derived GSC line established from human glioblastoma, to evaluate the efficacy of photodynamic therapy (PDT) using talaporfin sodium (NPe6)—a second-generation photosensitizer—and a semiconductor laser approved for clinical use in Japan. Under favorable oxygenation conditions, NPe6-PDT induced a dose- and fluence-dependent suppression of mitochondrial metabolic activity in MGG8 cells, mirroring responses previously observed in conventional glioblastoma cell lines. A similar pattern of cell death was noted, with both apoptosis and necrosis occurring in a time-dependent manner. Secondary reactive oxygen species (ROS) levels were also increased following PDT, indicating sustained intracellular oxidative stress. Given that GSC resistance is partly attributed to hypoxic microenvironments that diminish treatment-induced oxidative damage, these findings suggest that strategies to enhance tissue oxygenation could improve the therapeutic efficacy of NPe6-PDT against GSCs. This study represents the first experimental system to investigate NPe6-PDT in patient-derived GSCs and provides a foundation for future translational research.